在周围动脉疾病中探索等离子体蛋白质组的热稳定性:在西洛斯塔治疗下生物物理发现
Dorottya Szabó1, László Benkő1, Dénes Lőrinczy2
1Department of Vascular Surgery, Medical School, University of Pécs, Pécs Ifjúság Str. 13, H-7624 Pecs, Hungary.
Pharmaceuticals (Basel, Switzerland)
|June 27, 2025
概括
在患有外周动脉疾病的患者中,基洛斯塔治疗改变了血蛋白热力学. 微分扫描热量计 (DSC) 与解卷揭示了蛋白质稳定性的变化,提供了一种新的监测方法.
科学领域:
- 生物物理学的生物物理.
- 治疗药物监测 治疗药物监测
- 蛋白质组学是指蛋白质组学
背景情况:
- 间歇性,是外周动脉疾病的症状,用西洛斯塔治疗.
- 之前的研究使用差分扫描热量计 (DSC) 探索了基洛斯塔对等离子体热力学特性的影响.
研究的目的:
- 为了提高DSC数据的解释,用于血蛋白转换在治疗中使用cilostazol使用deconvolution技术.
- 为了研究基洛斯塔诱导的血蛋白质组热力学变化.
主要方法:
- 差异扫描热量计 (DSC) 应用于来自治疗西洛斯塔的患者和对照组的血样本.
- 解卷数学方法用于分析DSC热展开的配置文件.
- 在治疗3个月的时间内进行纵向血液采样.
主要成果:
- 在治疗患者和对照人群之间,热展开概况的显著差异.
- 改变了纤维素和专的变化温度和度.
- 球蛋白的热稳定性变化和转移蛋白的结构刚度增加.
结论:
- 奇洛斯塔会诱导血蛋白的全身热力学变化.
- DSC与解卷结合是一种有前途的工具,用于检测与治疗相关的蛋白质稳定性改变.
- 观察到的生物物理变化可能表明分子适应,如改变的蛋白质相互作用或急性相反应.
更多相关视频
相关概念视频
Peripheral Artery Disease III: Interprofessional Care
33
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
33
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation
38
Clinical manifestationsPeripheral Arterial Disease (PAD) manifests through a range of symptoms, from the characteristic intermittent claudication to atypical presentations and severe complications in advanced stages. Intermittent claudication, a hallmark symptom of PAD, presents as exercise-induced muscle pain that typically resolves within minutes of rest. This pain is reproducible and stems from inadequate blood flow, leading to the accumulation of lactic acid produced during anaerobic...
38
Peripheral Artery Disease I: Introduction
35
Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
35
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
259
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
259
Peripheral Artery Disease IV: Nursing Management
47
The nursing management of a patient with peripheral artery disease (PAD) begins with a thorough assessment of the patient’s health history and clinical manifestations.AssessmentHealth History: Evaluate the patient’s history of hypertension, hyperlipidemia, family history of cardiovascular issues, and lifestyle factors such as dietary patterns, smoking, and physical activity.Physical Examination:Assess the affected extremity for decreased or absent peripheral pulses,...
47
Atherosclerosis III: Management
41
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
41


